Drug Profile

PALI 2108

Alternative Names: GT-2108; PALI-2108

Latest Information Update: 25 Sep 2026

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Giiant Pharma
Developer Giiant Pharma; Palisade Bio
Class Anti-inflammatories; Antifibrotics; Small molecules
Mechanism of Action Type 4 cyclic nucleotide phosphodiesterase inhibitors

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity Yes

Highest Development Phases

Phase I/II Crohn's disease
Phase I Ulcerative colitis

Most Recent Events

23 Sep 2026 The Health Canada approves Clinical Trial Application (CTA) for the phase II ASCENTRA-UC of PALI 2108 in Ulcerative colitis
11 Aug 2026 Palisade Bio plans a phase II ASCENTRA-CD trial for Crohn’s disease in the first quarter of 2027
11 Aug 2026 Palisade Bio plans a phase II ASCENTRA-UC trial for Ulcerative Colitis in the second half of 2026

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com